文献速递中医内科中药与中成药合理使用

玉屏通窍片治疗持续性变应性鼻炎的多中心随机双盲安慰剂对照III期临床试验

A multicenter, randomized, double-blind, placebo-controlled, parallel-group phase III clinical trial to assess the efficacy and safety of Yuping Tongqiao tablets in the treatment of persistent allergic rhinitis.
PubMed 文献 · J Ethnopharmacol · 2025-06-03

本研究为多中心、随机、双盲、安慰剂对照III期临床试验,共随机540例持续性变应性鼻炎(PAR)患者,按2:1分为试验组(玉屏通窍片,n=360)和安慰剂组(n=180),疗程4周。结果显示试验组TNSS平均下降最小二乘均值-2.56分,安慰剂组-1.74分(p<0.01),且鼻部症状应答率、中医症状评分和RQLQ评分均显著改善,不良事件轻微至中度且两组发生率相似。结论认为玉屏通窍片治疗PAR有效且安全。

要点

  • 4周疗程内鼻部症状应答率更高,中医症状与生活质量评分明显改善。
  • 不良事件轻微至中度,两组发生率相似,安全性可接受。

核心结论

  • 玉屏通窍片治疗持续性变应性鼻炎有效且安全。

研究设计与样本

  • 多中心、随机、双盲、安慰剂对照III期临床试验,随机540例PAR患者,试验组360例、安慰剂组180例(2:1),疗程4周。

主要发现

  • 试验组TNSS平均下降最小二乘均值-2.56分,安慰剂组-1.74分(p<0.01)。
  • 试验组4周鼻部症状应答率更高,中医症状评分和RQLQ评分显著改善。
  • 疗效随治疗时间延长而增加,不良事件轻微至中度且两组发生率相似。

关键数值与推荐

  • TNSS平均下降最小二乘均值:试验组-2.56分,安慰剂组-1.74分(p<0.01)。

临床怎么用

  • 可将玉屏通窍片作为持续性变应性鼻炎的4周疗程选择,关注鼻部症状与生活质量改善。

以上解读依据论文摘要(全文未开放获取或许可不允许翻译转载)。

原文

ETHNOPHARMACOLOGICAL RELEVANCE: Yuping Tongqiao Tablets is a classic traditional Chinese medicine (TCM) formula commonly employed in China for managing various ailments, especially allergic conditions. Clinical reports indicate its potential as an effective treatment for persistent allergic rhinitis. Nevertheless, there remains a dearth of placebo-controlled studies to definitively establish its safety and efficacy. AIMS OF THE STUDY: Allergic rhinitis (AR) is a global health problem with an annually increasing prevalence and no radical cure to date. This study aimed to evaluate the efficacy and safety of Yuping Tongqiao tablets for the treatment of persistent allergic rhinitis and to provide a basis for using Chinese herbal medicine to treat AR. MATERIALS AND METHODS: This was a multicenter, randomized, double-blind, placebo-controlled study of patients with PAR. A total of 540 patients with PAR were randomly assigned to the test group (n = 360) or the placebo group (n = 180) at a 2:1 ratio. The clinical trial lasted for 4 weeks, evaluating various outcomes including total nasal symptom scores, rhinoconjunctivitis quality of life questionnaire (RQLQ) scores, traditional Chinese medicine (TCM) symptom scores and The incidence of adverse events. RESULTS: A total of 768 participants were enrolled, with 540 randomized and 516 successfully completed the research. The experimental group using Yuping Tongqiao tablets showed a significant reduction in TNSS, with the least squares mean of the average decrease being -2.56 points, compared to -1.74 points in the placebo group (p < 0.01). The experimental group exhibited a higher nasal symptom response rate at 4 weeks, substantial clinical improvements, and notable enhancements in TCM symptoms and RQLQ scores. Treatment efficacy increased with duration, and adverse events were mild-to-moderate and occurred at similar rates in both groups. CONCLUSION: Yuping Tongqiao tablets have been proven to be an effective and safe medication for the treatment of PAR. TRIAL REGISTRATION: ChiCTR, ChiCTR2200061367. Registered June 22, 2022.

来源:J Ethnopharmacol,查看原文。版权归原作者所有。

引用

  1. Wang M, Wang J, Chen J, et al. A multicenter, randomized, double-blind, placebo-controlled, parallel-group phase III clinical trial to assess the efficacy and safety of Yuping Tongqiao tablets in the treatment of persistent allergic rhinitis. J Ethnopharmacol. 2025. PMID: 40473149. doi:10.1016/j.jep.2025.120091

供执业医师工作参考,不替代临床判断;数值与分级以指南原文为准。